Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
Pritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart · 2024
Read Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens by Pritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11727171.txt.
Description
Lung cancer cells that resist drug pairs are profiled by Raungrut and co-authors in a 2024 study. The team grew two resistant lines from a human lung cancer line over six months of drug exposure. One line resists a platinum drug and the other a taxane drug, both used as a pair in care.
Gene scans found a shared set of changed genes across both lines. One gene, tied to cell growth signals, stood out as a hub. Checks in public data and lab tests support its value as a marker. If the marker holds in patients, it could help doctors judge who will gain from the drug pair and who needs another plan.
Catalog record
| CREATOR | Pritsana Raungrut, Suchanan Tanyapattrapong, Thipphanet Masjon, Saowanee Maungchanburi, Paramee Thongsuksai, Peter C Hart |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |